Video - Results from #40

ASCO 2021 VL

Search

The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar Details The phase 3 JAVELIN Bladder 100 trial demonstrated that First-line maintenance therapy with avelumab + best supportive care (BSC) significantly prolonged overall survival (OS) compared with BSC alone, while the optimal timing for starting avelumab after completing first-line (1L) chemotherapy is still unknown. In a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meetin...
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi Details In this conversation with Alicia Morgans, MD, MPH, Karim Fizazi shares trial results from the phase II ODENZA trial presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ODENZA is a French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metasta...
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland Details Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, to discuss a retrospective analysis of the Medicare database from January 2009-Dec 2018 on the real-world use of advanced therapies over time and the use of patterns among racial minorities that are often under-represented in clinical trials. These data were presented at the ASCO 2021 Annual Meeting. The researchers examined 35,195 patients in...
Apalutamide Improves Overall Survival and rPFS While Preserving Health-Related Quality of Life in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Neeraj Agarwal Details The TITAN Study is the pivotal phase III trial demonstrating the benefit of apalutamide in mHSPC. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Neeraj Agarwal, MD, presented the health-related quality of life (HRQoL) data from this final analysis after cross-over from the phase III TITAN trial. In this conversation with Alicia Morgans, MD, MPH, he highlights this data. T...